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PERSPECTIVE

Lingo-1: a novel target in therapy for
Alzheimer’s disease?
Unraveling the causes underlying Alzheimer’s disease (AD) is certainly
one of the greatest challenges of this century for researchers. With advances in medicine and technology, the world is experiencing a demographic shift towards a growing elderly population. With this increasingly ageing population, the number of individuals being affected by
AD is booming. AD has a significant negative impact on the lives of the
individuals with the disorder, as well as creating a significant social and
economic burden for society. Although major advances have been established in our understanding of the molecular and pathological mechanisms underlying this devastating disorder during the last decades, the
causes for neuronal degeneration and its treatment remain elusive.
AD is a progressive, neurodegenerative disease characterized clinically by gradual cognitive decline including loss of memory, orientation
and reasoning, and is pathologically characterized by accumulation of
neurofibrillary tangles and amyloid plaques in the brain. These amyloid
plaques have different rates of growth throughout neocortical and hippocampal regions, and are formed from oligomers of amyloid-β (Aβ)
in the intracellular and extracellular space. Aβ is the result of proteolysis
of amyloid precursor protein (APP) by β and γ-secretase enzymes. The
accumulation of Aβ oligomers becomes progressively toxic and triggers
the start of neurodegenerative processes (Hardy and Selkoe, 2002). Here
we discuss the role of Lingo-1, or LERN1 (leucine-rich repeat neuronal
protein 1) in this process, a transmembrane protein which is highly
abundant in the brain and is implicated in numerous neurodegenerative disorders (Andrews and Fernandez-Enright, 2015), and demonstrate reasons suggesting its potential for a role in future AD therapy.
Lingo-1, selectively expressed on oligodendrocytes and neurons, is a
potent negative modulator of neuronal processes such as neuronal
survival, axonal integrity and myelination as well as oligodendrocyte
differentiation (Mi et al., 2005). Its action notably involves the Nogo
receptor (NgR) as a part of a co-receptor complex, which includes the
p75 neurotrophin receptor (p75NTR) or TNF receptor orphan Y (TROY)
(Shao et al., 2005). The resulting trimolecular receptor complex Lingo-1/NgR/p75 or Lingo-1/NgR/TROY activates rho-associated coiled
coil-containing protein kinase (RhoA/ROCK) signalling pathways, subsequently initiating a cascade of intracellular molecular events resulting
in the collapse of growth cones, preventing further axonal growth and
inhibiting myelination (Shao et al., 2005). The inhibition of Lingo-1
induced signalling pathways may be involved in the development of
future therapies for neurological disorders such as multiple sclerosis
and/or Alzheimer’s disease. In addition, the Lingo-1 gene (coding for
Lingo-1 protein) locus is part of a chromosomic region 15q24 which
has been involved in the genetic susceptibility of numerous psychiatric
and neurological disorders including autism, schizophrenia, depression
and late onset Alzheimer’s disease (Scott et al., 2003; Andrews and Fernandez-Enright, 2015), supporting our hypothesis of a role of Lingo-1
in the pathophysiology of Alzheimer’s disease.
Lingo-1: APP binding partner and generation of Aβ: The cleavage of
APP leading to the deposition of Aβ in plaques in AD brains is a key
pathological marker in the progression of the disease. As illustrated in
Figure 1, APP can be processed through an amyloidogenic pathway
with its cleavage by β-secretase producing soluble APPβ (sAPPβ) and
carboxy-terminal fragments (CTFβ). This membrane bound fragment
is then cleaved further by γ-secretase leading to the production of Aβ
peptides and a membrane bound C-terminal fragment (APP Intra-Cellular Domain or AICD) (Hardy and Selkoe, 2002). However, APP can
also be processed via non-amyloidogenic processes which begin with
cleavage by α-secretase to produce a soluble APPα (sAPPα) fragment
and a membrane bound C-terminal fragment (CTFα, shorter than
CTFβ). CTFα, can then be cleaved by presenilin PS-secretase to yield a
soluble N-terminal fragment (peptide 3 or p3), which has so far been reported to be harmless in cells, and AICD, which is implicated in nuclear
signaling and axonal protein transport.
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In healthy cells, the large majority of APP (> 90%) is processed
via the non-amyloidogenic pathways; however this proportion can
be modified with age, genetic and environmental factors. Since APP
is such an abundant membrane bound protein, it will also be endocytosed into cells and be processed by many organelles including the
endoplasmic reticulum, Golgi apparatus and recycled endosomes (Choy
et al., 2012). The generation of Aβ has been reported in the Golgi apparatus and in early endosomes, locations where proteins are sorted (Choy
et al., 2012) (including both β and γ secretase which are necessary for
APP cleavage).
Lingo-1 was recently found to be capable of binding directly to APP,
promoting its degradation through lysosomal proteolysis (de Laat et al.,
2015). Consequently, Aβ formation is reduced due to the decreased levels
of APP being processed via the amyloidogenic pathway (de Laat et al.,
2015). However, since Aβ levels were not examined as a part of the study
from de Laat et al. (2015). study, this hypothesis has unfortunately not
been fully validated. Previous work on the well-established HEK293 cell
line overexpressing APP with the Swedish double mutation (HEK293
APPsw) reported a physical interaction between Lingo-1 and APP, facilitating its access to β-secretase and/or inhibiting its cleavage by α-secretase, resulting in an increase in the production of Aβ fragments (Bai et
al., 2008). However, this interaction did not occur though the Leucine
Rich Repeats as previously demonstrated via deletional mutagenesis
(Stein and Walmsley, 2012), and was in contrast to the Leucine-rich repeat transmembrane 3 protein (LRRT3) also leading to Aβ production
(Majercak et al., 2006). When the same cell study was performed in
HEK293 cells expressing wild type APP, β-secretase cleavage was reduced
by Lingo-1, due to the different mechanisms by which APP is processed
between wild type (internalization and endosome pathway) and Swedish
mutation (occurring within the secretion pathway) (Rice et al., 2013).
Similarly to Lingo-1, its co-factor p75NTR was reported to activate
β-secretase cleavage of APP, leading to the generation of Aβ in the context of normal aging (Costantini et al., 2005). Interestingly the Lingo-1
co-receptor NgR, was shown to affect APP processing via an inverse relationship with the secretion Aβ fragment levels (Park and Strittmatter,
2007). Altogether, since Lingo-1 and its signaling partners have been
shown to be highly involved in the generation of Aβ fragments, if the
effects of these partners on Aβ production with Lingo-1 induced-APP
proteolysis and/or β-cleavage of APP become unbalanced, this may lead
to amyloid plaque formation. Although Aβ production is necessary
for the normal healthy functioning of neurons, in excess it can have
dramatic consequences on synapses, resulting in neurodegenerative
processes.
Lingo-1 and its role in neuronal degeneration: Lingo-1 is widely expressed in the brain, notably within both the cerebral cortex and the
limbic system (Andrews and Fernandez-Enright, 2015). Both of these
regions play critical roles in essential brain functions such as integrated
thinking, emotion and memory processes. Levels of Lingo-1 expression
were reported to be reduced in the brains of post mortem AD patients
compared to their controls (in temporal, parietal and frontal cortical
areas) (de Laat et al., 2015). However, there was no description of how
diagnosis was established for these patients, no information regarding
the stage of development of AD, and no other demographic data were
available for any of the subjects (controls included) so this finding is to
be considered with caution and should be replicated and validated in
an established cohort for AD.
The regulation of axonal regeneration and neuronal survival by Lingo-1 involves a myriad of co-factors and co-receptors (Andrews and
Fernandez-Enright, 2015), including NgR/TROY and both the EGF receptor and its ligand. Lingo-1 and its signaling partners activate RhoA
which, in conjunction with ROCK, leads to the inhibition of axon outgrowth, oligodendrocyte maturation and neuronal survival (Andrews
and Fernandez-Enright, 2015). This downstream pathway also implicates the p75NTR receptor, which is responsible for transmitting intracellular signals. Interestingly, the levels of p75NTR receptor were found
to be upregulated in the postmortem hippocampus of AD sufferers
compared to healthy matched controlsand were found to stimulate APP
cleavage by β-secretase (while NgR was reported to increaseα-secretase for APP cleavage; Figure 2), (Chakravarthy et al., 2012). Lingo-1
can also directly inhibit the epidermal growth factor receptor (EGFR)
using EGFR-like tyrosine phosphorylation (Figure 2), resulting in its
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Figure 1 Schematization of Lingo-1 actions on APP metabolism in neurons.
Lingo-1 favors both β cleavage by β-secretase and APP lysosomal proteolysis.
APP: Amyloid precursor protein; Aβ: amyloid-beta peptides; AICD: APP Intra-Cellular Domain; CTF: carboxy-terminal fragments; Lingo-1: leucine-rich
repeat neuronal protein 1; p3: peptide 3; PS-secretase: preselinin-secretase; sAPP:
soluble APP.

internalization and degradation, and leading to a reduction in the activation of the Akt (or protein kinase B) signaling pathway (Andrews and
Fernandez-Enright, 2015). The inhibition of the Akt signaling pathway
consequently results in a reduction in neuronal survival, which contributes greatly to the neurodegenerative processes implicated in AD. EGFR
levels have also been reported to be upregulated in AD brains when
compared with healthy controls and were found as a preferred target
for treating Aβ-induced memory loss (Wang et al., 2012).
Altogether this shows that Lingo-1 downstream signaling is highly
involved in the pathophysiology of AD, notably in its neurodegenerative aspect. The modulation of the expression levels of these proteins
plays an essential role in AD brains, and depending on the way in
which these proteins are regulated, it may be enough to tip the balance
towards either healthy neuronal growth, or to the development of neurodegenerative processes (Figure 2). As illustrated in Figure 2, the implication of Lingo-1 in these neurodegenerative processes in the context
of AD occur through inhibition of vital signaling pathways (MEK2/3,
RhoA and Akt), but also through different Lingo-1 signaling partners
such as p75NTR and EGFR (Figure 2).
Conclusion: Is Lingo-1 a new target for AD therapy? In summary, it
appears that Lingo-1 plays a critical role in the pathophysiology of AD
by both favoring the β-cleavage of APP and the generation of Aβ fragments, but also by the activation of key molecular signaling pathways
leading to the inhibition of neuronal outgrowth and survival. An antibody targeting Lingo-1 (BIIB033 produced by Biogen®), has been engineered to be able to cross the blood-brain barrier and to antagonize
Lingo-1 within the central nervous system. This Lingo-1 antagonist is
currently in phase II clinical trials for treating multiple sclerosis and
may prove to be a promising treatment option for future AD therapies.
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Figure 2 The role of Lingo-1 pathways in neurodegeneration in the context of
Alzheimer’s disease.
EGFR: Epidermal growth factor receptor; ERK5: extracellular signal reduced
kinase 5; Lingo-1: leucine-rich repeat neuronal protein 1; MEK2/3: mitogen
activated protein kinase 2/3; NgR: Nogo receptor; p75NTR: p75 neurotrophin receptor; RhoA: ras homolog gene family, member A; PI3-K: phosphatidylinositide
3-kinase; PKB, also known as Akt: protein kinase B; ROCK: Rho-associated protein kinase; WNK1: WNK lysine deficient protein kinase 1.
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